Association of chemokine and chemokine receptor expression with the invasion and metastasis of lung carcinoma

Liu,Yan; Wu,Bing‑Quan; Geng,Hua; Xu,Mei‑Lin; Zhong,Hao‑Hao

doi:10.3892/ol.2015.3402

Association of chemokine and chemokine receptor expression with the invasion and metastasis of lung carcinoma

Authors:
- Yan Liu
- Bing‑Quan Wu
- Hua Geng
- Mei‑Lin Xu
- Hao‑Hao Zhong
View Affiliations

Affiliations: Department of Pathology, Peking University Health Science Center, Beijing 100191, P.R. China, Department of Pathology, Tianjin Chest Hospital, Tianjin 300051, P.R. China
Published online on: June 22, 2015 https://doi.org/10.3892/ol.2015.3402
Pages: 1315-1322
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The chemokine system has been reported to be utilized and manipulated by tumor cells in order to promote local tumor growth and distant dissemination. The present study aimed to investigate the expression of three chemokine ligand‑receptor axes in lung carcinoma tissues. Tumor and healthy normal tissue samples were obtained from 120 lung carcinoma patients following surgical resection. Immunohistochemistry and reverse transcription quantitative polymerase chain reaction were used in order to identify the protein and messenger (m)RNA expression of chemokines, including chemokine (C‑X‑C motif) ligand (CXCL)12/stromal cell‑derived factor (SDF)‑1, CXCL8/interleukin (IL)‑8, chemokine (C‑C motif) ligand (CCL)19 and CCL21, and the corresponding chemokine receptors, chemokine (C‑X‑C motif) receptor (CXCR)4, CXCR1, CXCR2 and chemokine (C‑C motif) receptor (CCR)7, respectively. The results revealed that compared with the normal lung tissues, lung carcinoma tissues expressed significantly higher mRNA levels of CXCL12/SDF‑1, CXCR4, CXCL8/IL‑8, CXCR2, CCL19 and CCR7 (P<0.01). In four histological subtypes, adenocarcinoma presented dominant expression of CXCR4, CXCR2, CXCL8/IL‑8 and CCL19 (P<0.05). In addition, it was demonstrated that tumor staging was inversely correlated with chemokine receptor CCR7 and CXCR2 mRNA expression as well as positively correlated with CXCL12/SDF‑1, CXCL8/IL‑8 and CCL19 mRNA levels (P<0.05). Lymph node metastasis presented a positive correlation with CXCR4, CXCR2 and CXCL8/IL‑8 expression and a negative correlation with CCL19 and CCR7 expression (P<0.05). Furthermore, vascular invasion was more prevalent in patients with higher expression levels of CXCR4, CCR7 or CCL19 (P<0.01). In conclusion, these data suggested that the ligand‑receptor interaction of CXCL8‑CXCR2, CXCL12‑CXCR4 and CCL19‑CCR7 may be involved in the tumorigenesis of lung carcinoma. Higher expression levels of chemokines and lower expression of chemokine receptors indicated poor tumor staging. The CXC chemokine receptors, CXCR4 and CXCR2, promoted lymphatic metastasis through the activation of their specific ligands, while CCL19 and its receptor CCR7 had an essential role in hematogenous metastasis of lung carcinoma.

View Figures

View References

1	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
2	Saintigny P and Burger JA: Recent advances in non-small cell lung cancer biology and clinical management. Discov Med. 13:287–297. 2012.PubMed/NCBI
3	Zlotnik A, Burkhardt AM and Homey B: Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol. 11:597–606. 2011. View Article : Google Scholar : PubMed/NCBI
4	Kakinuma T and Hwang ST: Chemokines, chemokine receptors and cancer metastasis. J Leukoc Biol. 79:639–651. 2006. View Article : Google Scholar : PubMed/NCBI
5	Keeley EC, Mehrad B and Strieter RM: CXC chemokines in cancer angiogenesis and metastases. Adv Cancer Res. 106:91–111. 2010. View Article : Google Scholar : PubMed/NCBI
6	Wald O, Shapira OM and Izhar U: CXCR4/CXCL12 axis in non small cell lung cancer (NSCLC) pathologic roles and therapeutic potential. Theranostics. 3:26–33. 2013. View Article : Google Scholar : PubMed/NCBI
7	Teicher BA and Fricker SP: CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res. 16:2927–2931. 2010. View Article : Google Scholar : PubMed/NCBI
8	Zhu YM, Webster SJ, Flower D and Woll PJ: Interleukin-8/CXCL8 is a growth factor for human lung cancer cells. Br J Cancer. 91:1970–1976. 2004. View Article : Google Scholar : PubMed/NCBI
9	Wiley HE, Gonzalez EB, Maki W, Wu MT and Hwang ST: Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. J Natl Cancer Inst. 93:1638–1643. 2001. View Article : Google Scholar : PubMed/NCBI
10	Mashino K, Sadanaga N, Yamaguchi H, et al: Expression of chemokine receptor CCR7 is associated with lymph node metastasis of gastric carcinoma. Cancer Res. 62:2937–2941. 2002.PubMed/NCBI
11	Tsim S, O'Dowd CA, Milroy R and Davidson S: Staging of non-small cell lung cancer (NSCLC): A review. Respir Med. 104:1767–1774. 2010. View Article : Google Scholar : PubMed/NCBI
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
13	Su L, Zhang J, Xu H, Wang Y, Chu Y, Liu R and Xiong S: Differential expression of CXCR4 is associated with the metastatic potential of human non-small cell lung cancer cells. Clin Cancer Res. 11:8273–8280. 2005. View Article : Google Scholar : PubMed/NCBI
14	Villena V, López-Encuentra A, García-Luján R, Echave-Sustaeta J and Martínez CJ: Clinical implications of appearance of pleural fluid at thoracentesis. Chest. 125:156–159. 2004. View Article : Google Scholar : PubMed/NCBI
15	Brave M, Farrell A, Ching Lin S, et al: FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation. Oncology. 78:282–288. 2010. View Article : Google Scholar : PubMed/NCBI
16	Burger JA, Stewart DJ, Wald O and Peled A: Potential of CXCR4 antagonists for the treatment of metastatic lung cancer. Expert Rev Anticancer Ther. 11:621–630. 2011. View Article : Google Scholar : PubMed/NCBI
17	Franco R, Pirozzi G, Scala S, et al: CXCL12-binding receptors expression in non-small cell lung cancer relates to tumoral microvascular density and CXCR4 positive circulating tumoral cells in lung draining venous blood. Eur J Cardiothorac Surg. 41:368–375. 2012. View Article : Google Scholar : PubMed/NCBI
18	Wagner PL, Hyjek E, Vazquez MF, et al: CXCL12 and CXCR4 in adenocarcinoma of the lung: association with metastasis and survival. J Thorac Cardiovasc Surg. 137:615–621. 2009. View Article : Google Scholar : PubMed/NCBI
19	Wald O, Izhar U, Amir G, et al: Interaction between neoplastic cells and cancer-associated fibroblasts through the CXCL12/CXCR4 axis: Role in non-small cell lung cancer tumor proliferation. J Thorac Cardiovasc Surg. 141:1503–1512. 2011. View Article : Google Scholar : PubMed/NCBI
20	Yatsunami J, Tsuruta N, Ogata K, et al: Interleukin-8 participates in angiogenesis in non-small cell, but not small cell carcinoma of the lung. Cancer Lett. 120:101–108. 1997. View Article : Google Scholar : PubMed/NCBI
21	Yuan A, Yang PC, Yu CJ, Chen WJ, Lin FY, Kuo SH and Luh KT: Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival and timing of relapse in non-small-cell lung cancer. Am J Respir Crit Care Med. 162:1957–1963. 2000. View Article : Google Scholar : PubMed/NCBI
22	Keane MP, Belperio JA, Xue YY, Burdick MD and Strieter RM: Depletion of CXCR2 inhibits tumor growth and angiogenesis in a murine model of lung cancer. J Immunol. 172:2853–2860. 2004. View Article : Google Scholar : PubMed/NCBI
23	Sparmann A and Bar-Sagi D: Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell. 6:447–458. 2004. View Article : Google Scholar : PubMed/NCBI
24	Gerber PA, Hippe A, Buhren BA, Müller A and Homey B: Chemokines in tumor-associated angiogenesis. Biol Chem. 390:1213–1223. 2009. View Article : Google Scholar : PubMed/NCBI
25	Legler DF, Uetz-von Allmen E and Hauser MA: CCR7: Roles in cancer cell dissemination, migration and metastasis formation. Int J Biochem Cell Biol. 54:78–82. 2014. View Article : Google Scholar : PubMed/NCBI
26	Wang J, Zhang X, Thomas SM, Grandis JR, Wells A, Chen ZG and Ferris RL: Chemokine receptor 7 activates phosphoinositide-3 kinase-mediated invasive and prosurvival pathways in head and neck cancer cells independent of EGFR. Oncogene. 24:5897–5904. 2005. View Article : Google Scholar : PubMed/NCBI
27	Takanami I: Overexpression of CCR7 mRNA in nonsmall cell lung cancer: Correlation with lymph node metastasis. Int J Cancer. 105:186–189. 2003. View Article : Google Scholar : PubMed/NCBI
28	Li P, Liu F, Sun L, et al: Chemokine receptor 7 promotes cell migration and adhesion in metastatic squamous cell carcinoma of the head and neck by activating integrin α vβ 3. Int J Mol Med. 27:679–687. 2011.PubMed/NCBI
29	Itakura M, Terashima Y, Shingyoji M, et al: High CC chemokine receptor 7 expression improves postoperative prognosis of lung adenocarcinoma patients. Br J Cancer. 109:1100–1108. 2013. View Article : Google Scholar : PubMed/NCBI
30	Su ML, Chang TM, Chiang CH, Chang HC, Hou MF, Li WS and Hung WC: Inhibition of chemokine (C-C motif) receptor 7 sialylation suppresses CCL19-stimulated proliferation, invasion and anti-anoikis. PLoS One. 9:e988232014. View Article : Google Scholar : PubMed/NCBI
31	Shields JD, Kourtis IC, Tomei AA, Roberts JM and Swartz MA: Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science. 328:749–752. 2010. View Article : Google Scholar : PubMed/NCBI
32	Koizumi K, Kozawa Y, Ohashi Y, et al: CCL21 promotes the migration and adhesion of highly lymph node metastatic human non-small cell lung cancer Lu-99 in vitro. Oncol Rep. 17:1511–1516. 2007.PubMed/NCBI
33	Zhang Q, Sun L, Yin L, Ming J, Zhang S, Luo W and Qiu X: CCL19/CCR7 upregulates heparanase via specificity protein-1 (Sp1) to promote invasion of cell in lung cancer. Tumour Biol. 34:2703–2308. 2013. View Article : Google Scholar : PubMed/NCBI
34	Lu J, Zhao J, Feng H, et al: Antitumor efficacy of CC motif chemokine ligand 19 in colorectal cancer. Dig Dis Sci. 59:2153–2162. 2014. View Article : Google Scholar : PubMed/NCBI
35	Hillinger S, Yang SC, Zhu L, et al: EBV-induced molecule 1 ligand chemokine (ELC/CCL19) promotes IFN-gamma-dependent antitumor responses in a lung cancer model. J Immunol. 171:6457–6465. 2003. View Article : Google Scholar : PubMed/NCBI
36	Hillinger S, Yang SC, Batra RK, Strieter RM, Weder W, Dubinett SM and Sharma S: CCL19 reduces tumour burden in a model of advanced lung cancer. Br J Cancer. 94:1029–1034. 2006. View Article : Google Scholar : PubMed/NCBI